WO1995032425A1 - Encoded combinatorial libraries - Google Patents

Encoded combinatorial libraries Download PDF

Info

Publication number
WO1995032425A1
WO1995032425A1 PCT/US1995/006392 US9506392W WO9532425A1 WO 1995032425 A1 WO1995032425 A1 WO 1995032425A1 US 9506392 W US9506392 W US 9506392W WO 9532425 A1 WO9532425 A1 WO 9532425A1
Authority
WO
WIPO (PCT)
Prior art keywords
beads
library
reaction
combinatorial
encoded
Prior art date
Application number
PCT/US1995/006392
Other languages
French (fr)
Inventor
Dennis Shinji Yamashita
Joseph Weinstock
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to JP7530459A priority Critical patent/JPH10500951A/en
Priority to US08/537,752 priority patent/US6210900B1/en
Priority to EP95920576A priority patent/EP0763202A4/en
Publication of WO1995032425A1 publication Critical patent/WO1995032425A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00497Features relating to the solid phase supports
    • B01J2219/005Beads
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/0054Means for coding or tagging the apparatus or the reagents
    • B01J2219/00572Chemical means
    • B01J2219/00576Chemical means fluorophore
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00592Split-and-pool, mix-and-divide processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00596Solid-phase processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718Type of compounds synthesised
    • B01J2219/0072Organic compounds
    • B01J2219/00725Peptides
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/10Libraries containing peptides or polypeptides, or derivatives thereof

Definitions

  • the field of this invention concerns combinatorial chemistry which involves the syntheses of one or more encoded combinatorial libraries where large numbers of products having varying compositions are obtained. This invention also relates to methods of encoding combinatorial libraries.
  • the standard method for conducting a search is to screen a variety of pre-existing chemical moieties, for example, naturally occurring compounds or compounds which exist in synthetic libraries or databanks.
  • the biological activity of the pre-existing chemical moieties is determined by applying the moieties to an assay which has been designed to test a particular property of the chemical moiety being screened, for example, a receptor binding assay which tests the ability of the moiety to bind to a particular receptor site.
  • Nonpeptidic organic compounds such as peptide mimetics
  • peptide mimetics can often surpass peptide ligands in affinity for a certain receptor of enzyme.
  • An effective strategy for rapidly identifying high affinity biological ligands, and ultimately new and important drugs, requires rapid construction and screening of diverse libraries of non-peptidic structures containing a variety of structural units capable of establishing one or more types of interactions with a biological acceptor (e.g., a receptor or enzyme), such as hydrogen bonds, salt bridges, pi-complexation, hydrophobic effects, etc.
  • a biological acceptor e.g., a receptor or enzyme
  • a key unsolved problem in the area of generation and use of nonpeptide libraries is the generation and use of nonpeptide libraries is the elucidation of the structure of molecules selected from a library that show promising biological activity.
  • An attempt to uncover the structures of peptides selected from a library using unique nucleotide sequence codes, which are synthesized in tandem with the peptide library, has been described by Brenner and Lerner (Brenner, S. and Lerner, R.A. Proc. Nat'l. Acad. Sci. USA, 1992 89 . 5381-5383).
  • the nucleotide sequence of the code attached to each peptide must be amplifiable via the polymerase chain reaction (PCR).
  • nucleotide synthesis techniques are not compatible with all of the synthetic techniques required for synthesis of many types of molecular libraries.
  • the close proximity of nucleotide and synthetic test compound in the library which can result in interactions between these molecules interfering with the binding of the ligand with a target receptor of enzyme during the biological assay, also limits this approach.
  • the nucleotide component of the library can also interfere during biological assays in a variety of other ways.
  • Kerr et al. J, Am, Chem, Soc., 1993, 115, 2520-2531
  • the peptide ligand and its coding strand in this library are covalently joined together, which allows isolation and sequence determination of pairs of synthetic test compound and corresponding code.
  • the coding peptide may interfere with the screening assay.
  • PCT/US93/09345 describes a method of identifying actives in a
  • combinatorial library by attaching multiple tags in a predetermined binary coding system.
  • PCT/HU93/0030 describes fluorescently labeled sub-library peptide kits for use in peptide synthesis.
  • PCT/US94/06078 describes methods of encoding combinatorial libraries using polymeric sequences.
  • This invention relates to a method for identifying compounds having desired characteristics and identifying essential moieties in a lead structure which comprises preparing one or more encoded combinatorial libraries from a specified set of reaction sequences and testing compounds therein for biological activity.
  • This invention also relates to a method of encoding a single registry in each combinatorial library of a series of combinatorial libraries and combinatorial libraries with a single encoded registry.
  • This invention also relates to a method of encoding combinatorial libraries which comprises utilization of tagged beads.
  • This invention also relates to a method of encoding each choice of a combinatorial library and combinatorial libraries encoded thereby.
  • This invention also relates to beads with fluorescently labeled identifiers attached thereto.
  • beads means any solid support material capable of providing a base for combinatorial syntheses and capable of being processed by flow cytometry, such as 1 to 2% crosslinked polystyrene, polyacrylamide, polyethylene glycol polystyrene co-polymer, preferably Tentagel 10 to 100 micron particles, most preferably Tentagel 10-30 micron particles.
  • sort means to form beads into groups which have a common tagging aspect by flow cytometry.
  • the term "separate” or “split” when referring to encoded beads or beads of a combinatorial library means to partition the mixture of beads into groups, each group thereinby containing a mixture, preferably a statistical mean of all members.
  • the term "tag”, unless otherwise indicated, means an encoding characteristic of a bead or group of beads which is capable of being sorted by flow cytometry, such as differences in size, differences in material composition, differences in flow properties, a single fluorescent marker or, preferably, a fluorescent label identifier.
  • fluorescent label identifier or "identifier” means a coding label attached to a bead or group of beads either by adding ratios of a fluorophore and a non-fluorophore or by adding multiple, preferably two, different fluorophores in varying ratios.
  • the term "intensity-differentiated” means an identifier (as used herein) in which varying ratios of a fluorophore and a non-fluorophore are added to a bead or group of beads.
  • the term "choice” means the alternative variables for a given stage in a combinatorial synthesis (not limited to peptide chemistry), such as reactant, reagent, reaction conditions, and combinations thereof.
  • stage corresponds to a step in the sequential synthesis of a compound or ligand; the compound or ligand being the final product of a combinatorial synthesis.
  • registration has the same meaning as the term "stage” as indicated above.
  • a series of combinatorial libraries are prepared, each individual library being prepared from substantially the same specified set of reaction sequences, therein encoding a single registry within each combinatorial library and analyzing according to mixtures of compounds with a homogeneous registry.
  • the specific encoded registry of any library will be different from the other libraries and the number of libraries prepared will equal the number of registries in a single library.
  • the number of readily identifiable groups of beads will correspond to the number of choices in the first registry, the entirety of each group is entered into a separate container.
  • the beads will usually be divided up into groups of at least one bead each, usually a plurality of beads, generally 1000 or more, and may be 10 5 or more depending on the total number of registries involved in the library.
  • the same reaction may be carried out in 2 or more containers to enhance the proportion of product having a particular reaction in a particular registry as compared to the other choices.
  • one or more of the registries may involve a portion of the beads being set aside and undergoing no reaction, so as to enhance the variability associated with the final product.
  • batches may be taken along different synthetic pathways. The library thus prepared will contain tagged beads which identify the reaction sequence of the first registry only.
  • a combinatorial library containing tagged beads which identify the reaction sequence of the first registry only can be prepared as outlined in Scheme 1 below.
  • Scheme 1 outlines the preparation of a combinatorial library in which only the first registry has been encoded.
  • beads with attached fluorescently labeled identifiers are derivatized with a linker that allows for cleavage of the compound to be tested.
  • each group of similarly tagged beads is entered into a separate container and subjected to specified reaction conditions (or variable building blocks, as used herein) to form the first registry.
  • specified reaction conditions or variable building blocks, as used herein
  • the beads In carrying out the synthesis to prepare the second library, one will preferably begin with the same number of beads as used in the first library, said beads may be tagged in a similar manner as in the first library.
  • the beads for use in the second library are first combined into a single mixture and then separated according to the number of choices for the first registry.
  • schemeSchoices for each registry of the second library and all subsequent libraries will be substantially the same as the synthetic schemeSchoices of the corresponding registry in the first library.
  • the reaction(s) may wish to wash the beads free of any reagent, followed by combining all of the beads into a single mixture and then separating the beads according to the number choices in the third registry of the first library. This procedure of dividing beads, followed by the synthetic scheme(s) ⁇ choice(s) from the corresponding registry of the first library, and then recombining the beads is iterated until the second library in completed.
  • the library thus prepared will contain tagged beads which identify the reaction sequence of the second registry only.
  • a combinatorial library containing tagged beads which identify the reaction sequence of the second registry only can be prepared as outlined in Scheme 2 below.
  • step 4 Deprotect FMOC; couple FMOC-NHCHR B1-BN CO 2 H. 5) Combine and separate. 6) Repeat step 4 and 5, except replace FMOC-NHCHR B 1-BN CO 2 H with FMOC-NHCHR C1-CN CO 2 H, ... FMOC-NHCHR X1-XN CO 2 H until the synthesis is complete.
  • Scheme 2 outlines the preparation of a combinatorial library in which only the second registry has been encoded.
  • beads with attached fluorescent label identifiers are first combined into a single mixture and then separated into groups according to the number of choices in the first registry of the first library . Subsequently, each group is entered into a separate container and subjected to the same reaction conditions of the first registry of the first library to form the first registry of the second library. Once the reaction(s) is complete the beads are combined into a single mixture and then sorted into groups according to similarly tagged beads. Preferably this combination of beads will be sorted using flow cytometry.
  • Each group of similarly tagged beads is entered into a separate container and subjected to the same reaction conditions of the second registry of the first library to form the second registry of the second library.
  • the beads are combined into a single mixture and then separated according to the number of choices in the third registry of the first library and reacted accordingly.
  • This procedure of dividing the beads, fo by subjection to specified reaction conditions from the corresponding ⁇ of the first library, and then recombining the beads is iterated until the second horary is completed.
  • the completed library is then tested for biological activity. Information on the relative activities of mixtures of the compounds with a homogeneous second registry is obtained from this library.
  • the above process is repeated to prepare subsequent libraries (when desired), provided that the sorting procedure is performed prior to a different synthetic stage in each library.
  • the combinatorial libraries thus prepared will contain tagged beads which identify the reaction sequence of a single registry only. Further, the identifiable ⁇ encoded registry in each combinatorial library will be different. Subsequent Combinatorial Libraries
  • each library is tested separately for biological activity.
  • testing for biological activity or "testing for desired
  • the compounds of a library may be tested on the beads, for example by bio-panning using a soluble receptor assay, and the activities analyzed preferably by flow cytometry.
  • the contents of the library may be sorted preferably by flow cytometry and the compounds tested on the beads, or the sorted compounds cleaved from the beads prior to testing.
  • Analysis of the first combinatorial library will yield the SAR of variable building block A.
  • Analysis of the second combinatorial library will yield the SAR of variable building block B.
  • Analysis of the third combinatorial library will yield the SAR of variable building block C.
  • Analysis of the SARs of the three variable building blocks (A, B and C) will identify desired reaction sequences and suggest multiple lead structures.
  • fluorescent label identifiers when referring to
  • flow cytometers are able to sort beads that differ in fluorescence intensity by a factor of 2.
  • the principles of flow cytometry and general methods for using flow cytometry are described in Grogan and Collins, Guide to Flow Cytometry Methods, Pub: Marcel Dekker, Inc. (1990).
  • intensity-differentiated fluorophore-labeled beads can be prepared by the method outlined in Scheme 3 below and in the Examples.
  • R is a fluorescent tag T 1 or a doping agent
  • D and R' is a fluorescent tagT 2 or a doping agent D, provided that when R is D, R' is other that D.
  • a sample of beads is derivatized with a linker, preferably ⁇ -Boc-FMOC lysine, by standard coupling chemistry.
  • a linker preferably ⁇ -Boc-FMOC lysine
  • a benzyl alcohol linker such as used with the Wang linker or a benzyl halide linker such as used with the Merrifield linker, or a benzhydryl amine linker as used with the Rink linker can be attached to the beads by the formation of ethers by alkylation of alcohols, alkylation or arylation by Friedl Crafts chemistry, the formation of biaryls by palladium mediated cross-coupling chemistry or by standard amide coupling chemistry.
  • a mono- deprotection step such as 20% piperdine/ DMF, for removal of an FMOC is performed.
  • the beads are then divided into N pools.
  • Pool 1 is derivatized with a fluorophore, such as pyrene butyric acid.
  • Pool 2 is derivatized with a 1:3 mixture of a fluorophore, such as pyrene butyric acid, and a non-fluorophore (hereinafter a "doping agent"), such as butyric acid or a different fluorophore, such as perylene butyric acid.
  • a fluorophore such as pyrene butyric acid
  • a non-fluorophore hereinafter a "doping agent”
  • Pool N is derivatized with a 1: 3 (N-1) ratio of a fluorophore, such as pyrene butyric acid, and a doping agent, such as butyric acid or a different fluorophore, such as perylene butyric acid.
  • a fluorophore such as pyrene butyric acid
  • a doping agent such as butyric acid or a different fluorophore, such as perylene butyric acid.
  • Each of these pools of beads can be differentiated from any other pool of beads by flow cytometry.
  • Each pool of beads may also be differentiated from one another by inspection with the unaided eye, however fewer variables could be encoded this way.
  • different fluorophores with different absorption and emittance wavelengths and multiple fluorophores could be encoded by fluorescence quenching to encode additional variables.
  • the use of multiple fluorophores, the ratio of which is the identifier has several advantages including the ability to greatly increases the number of variables that can be identified by using the same number of tags and enabling analysis independent of bead size.
  • the same strategy can be applied to prepare beads that can be used to discriminate between library members with redundant molecular weights by fluorescence, preferably by starting with beads with at least 50 pmoles of linker.
  • a single combinatorial library is prepared, each choice therein being encoded by a tag, preferably using fluorescent label identifiers, and tested for biological activity, preferably without mixing the final pools.
  • the “Combine and Split protocol” is utilized to synthesize encoded beads, preferably with fluorescent label identifiers attached thereto.
  • the “Combine and Split protocol” is advantageous in that it eliminates the need to resynthesize, or parallel synthesize, libraries containing only one or two fluorescent tags. This aspect of the invention is especially attractive from a practical point of view since the encoded beads can be prepared in bulk, prior to the actual synthesis of combinatorial libraries.
  • An additionally preferred aspect of this invention relates to combinatorial libraries prepared using beads encoded by fluorescent label identifiers and to pharmaceutically active compounds identified by such combinatorial library.
  • An additionally preferred aspect of this invention relates to combinatorial libraries in which each choice therein is encoded by fluorescent label identifiers and to pharmaceutically active compounds identified by such combinatorial library.
  • An additionally preferred aspect of this invention relates to combinatorial libraries prepared using beads encoded by fluorescent label identifiers, wherein said beads were obtained by the Combine and Split protocol, and to pharmaceutically active compounds identified by such combinatorial library.
  • An additionally preferred aspec his invention relates to combinatorial libraries in which each choice therein is encoded by fluorescent label identifiers, wherein said beads were obtained by the Combine and Split protocol, and to pharmaceutically active compounds identified by such combinatorial library.
  • Y 1 is encoded by Y 2 is encoded by Y 3 is encoded by T 1c T 2c T 3c
  • the above T 1 a Registry The above T 2a Registry
  • the above T 3a Registry can be described as can be described as can be described as can be described as can be described as
  • Z 1 is encoded by Z 2 is encoded by Z 3 is encoded by T 1a T 2a T 3a
  • T 1 b P 2 is encoded by T 2b
  • Scheme 4 outlines the preparation of a combinatorial library in which each choice therein is encoded by a unique identifier.
  • untagged beads are encoded with the first identifier (as described in Scheme 3).
  • the encoded beads are combined into a single mixture and then separated into groups according to the number of permutations of the second identifier.
  • the beads are then encoded with the second identifier. (The above encoding process is repeated until groups of encoded beads of desired size is obtained).
  • the beads encoded with the second identifier are combined into a single mixture and then separated into groups according to the number of permutations of the third identifier.
  • the beads are then encoded with the third identifier.
  • Encoded beads prepared according to the above methods and said methods represent preferred embodiments of the claimed invention.
  • the beads thus prepared are maintained in separate homogeneous pools of like identifiers according to the third identifier and subjected to the first stage (or registry as used herein) of specified reaction conditions.
  • the choices of the first registry are thereinby encoded by the third identifier.
  • the beads are then combined and sorted, preferably by flow cytometry, into homogeneous pools of like identifiers according to the first identifier.
  • the beads thus obtained are maintained in separate pools and subjected to the second stage of specified reaction conditions.
  • the choices of the second registry are thereinby encoded by the first identifier.
  • the beads are then combined and sorted, preferably by flow cytometry, into
  • the beads thus obtained are maintained in separate pools and subjected to the third stage of specified reaction conditions.
  • the choices of the third registry are thereinby encoded by the second identifier.
  • the beads are then combined and separated into groups according to the number of choices of the forth stage and subjected to the forth stage of specified reaction conditions.
  • the pools of beads thus obtained are maintained in these separate groups and tested for biological activity.
  • the choices of the forth registry are thereinby separately maintained.
  • each of these groups are separately tested for biological activity and analyzed, preferably by flow cytometry or by cleavage of compounds from individual groups or from smaller sets of individual groups.
  • the exact reaction history of each active can be identified by reading the unique identifier from the corresponding bead.
  • an active compound is found in group 2 then one could analyze the individual bead by fluorescence detection. If T 3c , T 2a , T 2b were present on the bead, then the reaction history of the active structure is: Y 3 -Z 2 -P 2 -Q 2 .
  • a bifunctional linker such as e-Boc-FMOC-L- lysine (8.4 g, 6 eq., 18 mmol, Novabiochem), an amide coupling agent such as diisopropyl carbodiimide ( 2.3 g, 2.8 ml, 6 eq., 18 mmol, Aldrich) is added to Polyethylene glycol-linked to cross-linked polystyrene beads (Tentagel M NH 2 , 10 micron particle size, 15.0 g, 3 mmol, Rapp Polymere) suspended in a suitable solvent such as N-methyl pyrrolidine (300 ml) and is agitated overnight The reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 100 ml).
  • a suitable solvent such as N-methyl pyrrolidine
  • the lysine derivatized beads (5.0 g), as described in Procedure A, are suspended in N-methyl pyrrolidine (100 ml), then a fluorophore such as 1-pyrene butyric acid (1.7 g, 6 eq., 6 mmol, Aldrich) and diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) are added, and the reaction is agitated for 3 hours.
  • the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
  • the beads are then agitated in 25% TFA/CH 2 CI 2 (100 ml) for 2 h removing the Boc protective group.
  • the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried.
  • the beads are then reacted with a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
  • a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
  • the reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 100 ml), then air dried.
  • the beads are then re suspended in THF ( 100 ml), and a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
  • a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
  • the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried.
  • the beads ( 5 g), as prepared in Procedure B, are then suspended in N- methyl pyrrolidine (100 ml) and is then reacted with a monomer such as FMOC-L- glyine (1.8 g, 6 eq., 6 mmol).
  • a monomer such as FMOC-L- glyine (1.8 g, 6 eq., 6 mmol).
  • Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
  • the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
  • Procedure D The lysine derivatized beads (5.0 g), as described in Procedure A, are suspended in N-methyl pyrrolidine (100 ml), then a fluorophore such as 1-pyrene butyric acid (0.43 g, 1.5 eq., 1.5 mmol), and a doping agent such as butyric acid (0.4 g, 0.41 ml, 4.5 eq., 4.5 mmol) in 1:3 stoichiometry, and diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) are added, and the reaction is agitated for 3 hours.
  • a fluorophore such as 1-pyrene butyric acid (0.43 g, 1.5 eq., 1.5 mmol)
  • a doping agent such as butyric acid (0.4 g, 0.41 ml, 4.5 eq., 4.5 mmol) in 1:3 stoichiometry
  • reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
  • the beads are then agitated in 25% TFA/ CH 2 CI 2 (100 ml) for 2 h removing the Boc protective group.
  • the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried.
  • the beads are then reacted with a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
  • a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
  • the reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 100 ml), then air dried.
  • the beads are then resuspended in THF (100 ml), and a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
  • a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
  • the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried.
  • the beads ( 5 g), as prepared in Procedure D, are then suspended in N- methyl pyrrolidine (100 ml) and is then reacted with a monomer such as FMOC-L- alanine (1.9 g, 6 eq., 6 mmol).
  • a monomer such as FMOC-L- alanine (1.9 g, 6 eq., 6 mmol).
  • Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
  • the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
  • the lysine derivatized beads (5.0 g), as described in Procedure A, are suspended in N-methyl pyrrolidine (100 ml), then a fluorophore such as 1-pyrene butyric acid (0.173 g, 0.6 eq., 0.6 mmol), and a doping agent such as butyric acid (0.48 g, 0.49 ml, 5.4 eq., 5.4 mmol) in 1:9 stoichiometry, and diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) are added, and the reaction is agitated for 3 hours.
  • a fluorophore such as 1-pyrene butyric acid (0.173 g, 0.6 eq., 0.6 mmol)
  • a doping agent such as butyric acid (0.48 g, 0.49 ml, 5.4 eq., 5.4 mmol) in 1:9 stoichiometry,
  • Th e reaction is filtered through a glass frit under aspirator pressure, washed with DMH ( 5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
  • the beads are then agitated in 25% TFA/ CH 2 CI 2 (100 ml) for 2 h removing the Boc protective group.
  • the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried.
  • the beads are then reacted with a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
  • a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
  • the reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 100 ml), then air dried.
  • the beads are then resuspended in THF (100 ml), and a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
  • a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
  • the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried.
  • the beads ( 5 g), as prepared in Procedure F, are then suspended in N- methyl pyrrolidine (100 ml) and is then reacted with a monomer such as FMOC-L- phenylalanine (2.3 g, 6 eq., 6 mmol).
  • a monomer such as FMOC-L- phenylalanine (2.3 g, 6 eq., 6 mmol).
  • Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
  • the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
  • Pool H1 is reacted with a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol).
  • a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol).
  • Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
  • the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
  • Pool H2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol).
  • Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
  • the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
  • Procedure J The beads obtained from Procedure I are then combined and sorted by flow cytometry into different sublibraries differentiated by the differences in intensity of fluorescence. Sublibrary components have the same first amino acid of the tripeptide.
  • Sublibrary J1 consists of Gly-X-X or Gly-Gly-Gly, Gly-Gly-Ala, Gly-Gly-Phe, Gly- Ala- Gly, Gly-Ala-Ala, Gly-Ala-Phe, Gly-Phe-Gly, Gly-Phe-Ala, Gly-Phe-Phe.
  • Sublibrary J2 consists of Ala-X-X or Ala-Gly-Gly, Ala-Gly-Ala, Ala-Gly-Phe, Ala- Ala- Gly, Ala-Ala- Ala, Ala-Ala-Phe, Ala-Phe-Gly, Ala-Phe-Ala, Ala-Phe-Phe
  • Sublibrary J3 consists of Phe-X-X or Phe-Gly-Gly, Phe-Gly-Ala, Phe-Gly-Phe, Phe- Ala- Gly, Phe-Ala-Ala, Phe-Ala-Phe, Phe-Phe-Gly, Phe-Phe-Ala, Phe-Phe-Phe-Phe
  • Pool M2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol).
  • a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol).
  • Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
  • the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
  • Pool M3 is reacted with a monomer such as FMOC-L-phenylalanine (2.3 g, 6 eq., 6 mmol).
  • Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
  • the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
  • the beads obtained from Procedure M are then combined and sorted by flow cytometry into different sublibraries differentiated by the differences in intensity of fluorescence.
  • Sublibrary components have the same second amino acid of the tripeptide.
  • Sublibrary N1 consists of X-Gly-X or Gly-Gly-Gly, Gly-Gly- Ala, Gly-Gly-Phe, Ala- Gly-Gly, Ala-Gly-Ala, Ala-Gly-Phe, Phe-Gly-Gly, Phe-Gly-Ala, Phe-Gly- Phe
  • Sublibrary N2 consists of X-Ala-X or Gly-Ala-Gly, Gly- Ala- Ala, Gly-Ala-Phe, Ala- Ala- Gly, Ala- Ala- Ala, Ala-Ala-Phe, Phe-Ala-Gly, Phe-Ala-Ala, Phe-Ala- Phe
  • Sublibrary N3 consists of X-Phe-X or Gly-Phe-Gly, Gly-Phe-Ala, Gly-Phe-Phe, Ala-Phe- Gly, Ala-Phe-Ala, Ala-Ala-Phe, Phe-Phe-Gly, Phe-Phe-Ala, Phe- Phe-Phe-Phe
  • the beads obtained from Procedure P are then combined and sorted by flow cytometry into different pools differentiated by the differences in intensity of fluorescence.
  • the pools of beads obtained from Procedure Q are already sorted into sublibraries in which the third amino acid of each component is the same the same amino acid of the tripeptide.
  • Sublibrary Q1 consists of X-X-Gly or Gly-Gly-Gly, Gly-Ala-Gly, Gly-Phe-Gly,
  • Sublibrary Q2 consists of X-X-Ala or Gly-Gly- Ala, Gly- Ala- Ala, Gly-Phe- Ala,
  • Ala-Gly- Ala Ala- Ala- Ala, Ala-Phe-Ala, Phe-Gly-Ala, Phe-Ala-Ala, Phe-
  • Sublibrary Q3 consists of X-X-Phe or Gly-Gly-Phe, Gly-Ala-Phe, Gly-Phe-Phe,
  • Example 1 The methods of Example 1 are used except that the doping reagent is replaced by a second fluorophore such as perylene butyric acid.
  • a second fluorophore such as perylene butyric acid.

Abstract

Invented is a method of preparing combinatorial libraries and combinatorial libraries prepared thereby. Also invented is a method for identifying compounds having desired characteristics from a combinatorial library or a set of combinatorial libraries by the use of flow cytometry. Also invented is a method for encoding combinatorial libraries using fluorophore labeled beads.

Description

ENCODED COMBINATORIAL L IBRARIES
FIELD OF THE INVENTION
The field of this invention concerns combinatorial chemistry which involves the syntheses of one or more encoded combinatorial libraries where large numbers of products having varying compositions are obtained. This invention also relates to methods of encoding combinatorial libraries.
BACKGROUND OF THE INVENTION
In the continuing search for new chemical moieties that can effectively modulate a variety of biological processes, the standard method for conducting a search is to screen a variety of pre-existing chemical moieties, for example, naturally occurring compounds or compounds which exist in synthetic libraries or databanks. The biological activity of the pre-existing chemical moieties is determined by applying the moieties to an assay which has been designed to test a particular property of the chemical moiety being screened, for example, a receptor binding assay which tests the ability of the moiety to bind to a particular receptor site.
In an effort to reduce the time and expense involved in screening a large number of randomly chosen compounds for biological activity, several
developments have been made to provide libraries of compounds for the discovery of lead compounds. The chemical generation of molecular diversity has become a major tool in the search for novel lead structures. Currently, the known methods for chemically generating large numbers of molecularly diverse compounds generally involve the use of solid phase synthesis, in particular to synthesize and identify peptides and peptide libraries. See, for example, Lebl et al., Int. J. Pept. Prot. Res., 41, p. 201 (1993) which discloses methodologies providing selectively cleavable linkers between peptide and resin such that a certain amount of peptide can be liberated from the resin and assayed in soluble form while some of the peptide still remains attached to the resin, where it can be sequenced; Lam et al., Nature, 354, p. 82 (1991) and (WO 92/00091) which disclose a method of synthesis of linear peptides on a solid support such as polystyrene orpolyacrylamide resin; Geysen et al., J. Immunol. Meth., 102, p. 259 (1987) which discloses the synthesis of peptides on derivatized polystyrene pins which are arranged on a block in such a way that they correspond to the arrangement of wells in a 96-well microtiter plate; and Houghten et al., Nature, 354, p. 84 (1991) and WO 92/09300 which disclose an approach to de novo determination of antibody or receptor binding sequences involving soluble peptide pools.
The major drawback, aside from technical considerations, with all of these methods for lead generation is the quality of the lead. Linear peptides historically have represented relatively poor leads for pharmaceutical design. In particular, there is no rational strategy for conversion of a linear peptide into a non-peptide lead. As noted above, one must resort to screening large databanks of compounds, with each compound being tested individually, in order to determine non-peptide leads for peptide receptors.
It is known that a wide variety of organic reactions can be carried out on substrates immobilized on resins. These include, in addition to peptide synthesis reactions which are well known to those of ordinary skill in the art, nucleophilic displacements on benzylic halides, halogenation, nitration, sulfonation, oxidation, hydrolysis, acid chloride formation, Friedel-Crafts reactions, reduction with
LiAlH4, metallation, and reaction of the organometallic polymer with a wide variety of reagents. See, for example, N. K. Mathur et al., Polymers as Aids in Organic Chemistry, Academic Press, New York, p. 18 (1980). In addition, Farrall et al., J. Org. Chem., 41, p. 3877 (1976) describe the experimental details of some of these reactions carried out with resins.
Nonpeptidic organic compounds, such as peptide mimetics, can often surpass peptide ligands in affinity for a certain receptor of enzyme. An effective strategy for rapidly identifying high affinity biological ligands, and ultimately new and important drugs, requires rapid construction and screening of diverse libraries of non-peptidic structures containing a variety of structural units capable of establishing one or more types of interactions with a biological acceptor (e.g., a receptor or enzyme), such as hydrogen bonds, salt bridges, pi-complexation, hydrophobic effects, etc. However, work on the generation and screening of synthetic test compound libraries containing nonpeptidic molecules is now in its infancy, one example from this area is the work of Ellman and Bunin on a combinatorial synthesis of benzodiazepines on a solid support (J. Am. Chem. Soc. 114, 10997, (1992); see Chemical and Engineering News, January 18, 1993, page 33).
A key unsolved problem in the area of generation and use of nonpeptide libraries is the generation and use of nonpeptide libraries is the elucidation of the structure of molecules selected from a library that show promising biological activity. An attempt to uncover the structures of peptides selected from a library using unique nucleotide sequence codes, which are synthesized in tandem with the peptide library, has been described by Brenner and Lerner (Brenner, S. and Lerner, R.A. Proc. Nat'l. Acad. Sci. USA, 1992 89 . 5381-5383). The nucleotide sequence of the code attached to each peptide must be amplifiable via the polymerase chain reaction (PCR). However, nucleotide synthesis techniques are not compatible with all of the synthetic techniques required for synthesis of many types of molecular libraries. Furthermore, the close proximity of nucleotide and synthetic test compound in the library, which can result in interactions between these molecules interfering with the binding of the ligand with a target receptor of enzyme during the biological assay, also limits this approach. The nucleotide component of the library can also interfere during biological assays in a variety of other ways.
Kerr et al. (J, Am, Chem, Soc., 1993, 115, 2520-2531) reported synthesizing solution phase libraries of peptides, containing non-natural amino acid residues, in parallel with peptide coding strands. The peptide ligand and its coding strand in this library are covalently joined together, which allows isolation and sequence determination of pairs of synthetic test compound and corresponding code.
However, as with the nucleic-acid-encoded library described by Brenner and Lerner, above, the coding peptide may interfere with the screening assay.
PCT/US93/09345 describes a method of identifying actives in a
combinatorial library by attaching multiple tags in a predetermined binary coding system.
PCT/HU93/0030 describes fluorescently labeled sub-library peptide kits for use in peptide synthesis.
PCT/US94/06078 describes methods of encoding combinatorial libraries using polymeric sequences.
Many of the disadvantages of the known methods as well as many of the needs not met by them are addressed by the present invention which, as described more fully hereinafter, provides numerous advantages over the known methods.
SUMMARY OF THE INVENTION
This invention relates to a method for identifying compounds having desired characteristics and identifying essential moieties in a lead structure which comprises preparing one or more encoded combinatorial libraries from a specified set of reaction sequences and testing compounds therein for biological activity. This invention also relates to a method of encoding a single registry in each combinatorial library of a series of combinatorial libraries and combinatorial libraries with a single encoded registry.
This invention also relates to a method of encoding combinatorial libraries which comprises utilization of tagged beads.
This invention also relates to a method of encoding each choice of a combinatorial library and combinatorial libraries encoded thereby.
This invention also relates to beads with fluorescently labeled identifiers attached thereto.
Detailed Description of the Invention
As used herein, the term "beads" means any solid support material capable of providing a base for combinatorial syntheses and capable of being processed by flow cytometry, such as 1 to 2% crosslinked polystyrene, polyacrylamide, polyethylene glycol polystyrene co-polymer, preferably Tentagel 10 to 100 micron particles, most preferably Tentagel 10-30 micron particles.
As used herein, the term "sort" means to form beads into groups which have a common tagging aspect by flow cytometry.
As used herein, the term "separate" or "split" when referring to encoded beads or beads of a combinatorial library means to partition the mixture of beads into groups, each group thereinby containing a mixture, preferably a statistical mean of all members.
As used herein, the term "tag", unless otherwise indicated, means an encoding characteristic of a bead or group of beads which is capable of being sorted by flow cytometry, such as differences in size, differences in material composition, differences in flow properties, a single fluorescent marker or, preferably, a fluorescent label identifier.
As used herein, the term "fluorescent label identifier" or "identifier" means a coding label attached to a bead or group of beads either by adding ratios of a fluorophore and a non-fluorophore or by adding multiple, preferably two, different fluorophores in varying ratios.
As used herein, the term "intensity-differentiated" means an identifier (as used herein) in which varying ratios of a fluorophore and a non-fluorophore are added to a bead or group of beads.
As used herein, the term "choice" means the alternative variables for a given stage in a combinatorial synthesis (not limited to peptide chemistry), such as reactant, reagent, reaction conditions, and combinations thereof. Where the term "stage" corresponds to a step in the sequential synthesis of a compound or ligand; the compound or ligand being the final product of a combinatorial synthesis. The term "registry", as used herein, has the same meaning as the term "stage" as indicated above.
In a preferred aspect of the invention a series of combinatorial libraries are prepared, each individual library being prepared from substantially the same specified set of reaction sequences, therein encoding a single registry within each combinatorial library and analyzing according to mixtures of compounds with a homogeneous registry. Preferably, the specific encoded registry of any library will be different from the other libraries and the number of libraries prepared will equal the number of registries in a single library.
In carrying out the synthesis to prepare the first library, one may initially begin with a number of beads, usually at least 103, more usually at least 104, and desirably at least 105, while generally not exceeding at least 1015 , more usually not exceeding at least 1010, characterized in that the beads are separated into groups, the beads within each group being similarly tagged and each group being uniquely tagged, preferably by an identifier, or one group being untagged and each of the remaining groups being uniquely tagged, preferably by an identifier. The number of readily identifiable groups of beads will correspond to the number of choices in the first registry, the entirety of each group is entered into a separate container. One can use microtiter well plates, flasks, Merrifield synthesis vessels, etc. The beads will usually be divided up into groups of at least one bead each, usually a plurality of beads, generally 1000 or more, and may be 105 or more depending on the total number of registries involved in the library.
One would then add the appropriate agents to each of the individual containers to process them in stages (or "registries" as used herein). Once the reaction(s) is complete, one may wish to wash the beads free of any reagent, followed by combining all of the beads into a single mixture and then separating the beads according to the number of choices for the next registry. The procedure of dividing beads, followed by a synthetic stage (to form a registry), and then recombining beads is iterated until the first combinatorial library is completed.
In some instances, the same reaction may be carried out in 2 or more containers to enhance the proportion of product having a particular reaction in a particular registry as compared to the other choices. In other instances, one or more of the registries may involve a portion of the beads being set aside and undergoing no reaction, so as to enhance the variability associated with the final product. In other situations, batches may be taken along different synthetic pathways. The library thus prepared will contain tagged beads which identify the reaction sequence of the first registry only.
A combinatorial library containing tagged beads which identify the reaction sequence of the first registry only can be prepared as outlined in Scheme 1 below.
Scheme 1
O
O
Figure imgf000008_0001
)
O
O2
Figure imgf000009_0001
- O2
O
O
-
Figure imgf000010_0001
1) Combine and separate.
2) Deprotect FMOC; couple FMOC-NHCHRB 1-BNCO2H.
3) Repeats steps 1 and 2, except replace FMOC-NHCHRB 1-BNCO2H with FMOC-NHCHRC 1-CNCO2 H, ... FMOC-NHCHRX 1-XNCO2H until the library synthesis is complete.
4) Sort beads by flow cytometry.
5a) Cleave compounds off of sorted beads or 5b) Test compounds directly attached to beads, preferably by bio-panning or flow cytometry.
Scheme 1 outlines the preparation of a combinatorial library in which only the first registry has been encoded. As used in Scheme 1 beads with attached fluorescently labeled identifiers are derivatized with a linker that allows for cleavage of the compound to be tested. Subsequently, each group of similarly tagged beads is entered into a separate container and subjected to specified reaction conditions (or variable building blocks, as used herein) to form the first registry. Once the reaction is complete the beads are combined into a single mixture and then separated according to the number of choices in the second registry and reacted. This procedure of dividing beads, followed by subjection to specified reaction conditions, and then recombining beads is iterated until the first library is completed. The completed library is then tested for biological activity. Information on the relative activities of mixtures of the compounds with a homogeneous first registry is obtained from this library.
In carrying out the synthesis to prepare the second library, one will preferably begin with the same number of beads as used in the first library, said beads may be tagged in a similar manner as in the first library. The beads for use in the second library are first combined into a single mixture and then separated according to the number of choices for the first registry. The synthetic
schemeSchoices for each registry of the second library and all subsequent libraries will be substantially the same as the synthetic schemeSchoices of the corresponding registry in the first library. Once the reaction(s) for the first registry of the second library is complete, one may wish to wash the beads free of any reagent, followed by combining all of the beads into a single mixture and then sorting the mixture into groups according to similarly tagged beads. Preferably this combination of beads will be sorted using flow cytometry. Once the beads from the first registry are sorted each group of similarly tagged beads is entered into a separate container and subjected to the same synthetic scheme(s)\choice(s) used for the second registry of the first library. Once the reaction(s) is complete, one may wish to wash the beads free of any reagent, followed by combining all of the beads into a single mixture and then separating the beads according to the number choices in the third registry of the first library. This procedure of dividing beads, followed by the synthetic scheme(s)\choice(s) from the corresponding registry of the first library, and then recombining the beads is iterated until the second library in completed. The library thus prepared will contain tagged beads which identify the reaction sequence of the second registry only.
A combinatorial library containing tagged beads which identify the reaction sequence of the second registry only can be prepared as outlined in Scheme 2 below.
Figure imgf000012_0001
(as prepared in Schemes 1 and 3)
1) Combine and separate.
2) Couple FMOC-NHCHRA 1-ANCO2H.
3) Combine and sort by flow cytometry.
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
4) Deprotect FMOC; couple FMOC-NHCHRB1-BNCO2H. 5) Combine and separate. 6) Repeat step 4 and 5, except replace FMOC-NHCHRB 1-BNCO2 H with FMOC-NHCHRC1-CNCO2H, ... FMOC-NHCHRX1-XNCO2 H until the synthesis is complete.
7) Combine and sort by flow cytometry.
8a) Cleave compounds off of sorted beads or
8b) Test compounds directly attached to beads, preferably by bio-panning or flow cytometry.
Scheme 2 outlines the preparation of a combinatorial library in which only the second registry has been encoded. As used in Scheme 2 beads with attached fluorescent label identifiers are first combined into a single mixture and then separated into groups according to the number of choices in the first registry of the first library . Subsequently, each group is entered into a separate container and subjected to the same reaction conditions of the first registry of the first library to form the first registry of the second library. Once the reaction(s) is complete the beads are combined into a single mixture and then sorted into groups according to similarly tagged beads. Preferably this combination of beads will be sorted using flow cytometry. Each group of similarly tagged beads is entered into a separate container and subjected to the same reaction conditions of the second registry of the first library to form the second registry of the second library. Once the reaction is complete the beads are combined into a single mixture and then separated according to the number of choices in the third registry of the first library and reacted accordingly. This procedure of dividing the beads, fo by subjection to specified reaction conditions from the corresponding
Figure imgf000017_0001
\ of the first library, and then recombining the beads is iterated until the second horary is completed. The completed library is then tested for biological activity. Information on the relative activities of mixtures of the compounds with a homogeneous second registry is obtained from this library.
The above process is repeated to prepare subsequent libraries (when desired), provided that the sorting procedure is performed prior to a different synthetic stage in each library. The combinatorial libraries thus prepared will contain tagged beads which identify the reaction sequence of a single registry only. Further, the identifiable\encoded registry in each combinatorial library will be different. Subsequent Combinatorial Libraries
The preparation of a combinatorial library in which the Xth registry has been encoded utilizes the same procedure as described in Scheme 2 except that the "combine and sort, preferably by flow cytometry" step is performed just prior to incorporation of the Xth variable building block. The completed library is then tested for biological activity. Information on the relative activities of mixtures of the compounds with a homogeneous Xth variable registry is obtained from this library.
After synthesis is complete, each library is tested separately for biological activity.
The term "testing for biological activity" or "testing for desired
characteristics" as used herein includes any form of testing for pharmaceutical activity including the methods indicated below. The compounds of a library may be tested on the beads, for example by bio-panning using a soluble receptor assay, and the activities analyzed preferably by flow cytometry. Alternatively, the contents of the library may be sorted preferably by flow cytometry and the compounds tested on the beads, or the sorted compounds cleaved from the beads prior to testing.
When all of the information is combined, a population analysis of each combinatorial library is obtained revealing which variable building block(s) are important for activity and which ones are not. This type of analysis is identical to Structure Activity Relationship (SAR) studies in which the analysis of actives and inactives identify essential moieties in a lead structure. In this analysis a particular lead structure may be obtained, further multiple lead structures are potentially obtained (as in positional scanning in peptide combinatorial libraries) and initial directions for further optimization are immediately suggested. The analysis of a three (3) registry-three (3) combinatorial library, prepared as in the above Schemes, is outlined in Table 1 below.
Table 1
First combinatorial library with encoded first Registry prepared as in
Figure imgf000018_0001
Second combinatorial library with encoded second Registry prepared as in Scheme 2 above.
Figure imgf000019_0001
Figure imgf000019_0002
Analysis of the first combinatorial library will yield the SAR of variable building block A. Analysis of the second combinatorial library will yield the SAR of variable building block B. Analysis of the third combinatorial library will yield the SAR of variable building block C. Analysis of the SARs of the three variable building blocks (A, B and C) will identify desired reaction sequences and suggest multiple lead structures.
In a further aspect of the invention there is provided a preferred method for encoding\tagging combinatorial libraries which utilizes fluorescent label identifiers. As used herein, the term "fluorescent label identifiers" when referring to
fluorophore labeled beads means:
i) that all of the beads in a given pool will have the same fluorescence intensity and different pools will have intensities that differ from any other pool by a factor of at least 2, preferably 3 or more or
ii) that multiple, preferably 2, different fluorescent tags are used in varying ratios such that all of the beads in a given pool will have the same combination of fluorescent tags in the same ratio and different pools will have:
a) the same fluorescent tags but in ratios that differ from any other pool,
b) a different set of fluorescent tags in a specified ratio or c) a combination of a) and b). It is known that flow cytometers are able to sort beads that differ in fluorescence intensity by a factor of 2. The principles of flow cytometry and general methods for using flow cytometry are described in Grogan and Collins, Guide to Flow Cytometry Methods, Pub: Marcel Dekker, Inc. (1990).
Intensity-differentiated fluorophore-labeled beads can be prepared by derivatizing pools of beads with varying amounts of a fluorophore and a non- fluorophore or by varying the reaction time of a single reactive fluorescent tag. Additionally, multiple, preferably 2, fluorescent tags can be used in varying ratios to encoded beads. This is preferably implemented, for example, by varying the stoichiometry of a first fluorescent tag (A) and a second fluorescent tag (B), such as A:B = 1:1, 1:2, 2:1, 1:4, 4:1, etc., in the tagging step(s).
As used herein, intensity-differentiated fluorophore-labeled beads can be prepared by the method outlined in Scheme 3 below and in the Examples.
Scheme 3
:3 - )
Figure imgf000021_0001
As used in Schemes 1 to 3 above, R is a fluorescent tag T1 or a doping agent
D and R' is a fluorescent tagT2 or a doping agent D, provided that when R is D, R' is other that D.
As used in Scheme 3 a sample of beads, preferably Tentagel, 10-30 micron particles, is derivatized with a linker, preferably ε-Boc-FMOC lysine, by standard coupling chemistry. Alternatively, a benzyl alcohol linker such as used with the Wang linker or a benzyl halide linker such as used with the Merrifield linker, or a benzhydryl amine linker as used with the Rink linker can be attached to the beads by the formation of ethers by alkylation of alcohols, alkylation or arylation by Friedl Crafts chemistry, the formation of biaryls by palladium mediated cross-coupling chemistry or by standard amide coupling chemistry. As used in Scheme 3, a mono- deprotection step, such as 20% piperdine/ DMF, for removal of an FMOC is performed. One could also run the tagging reaction to partial completion by limiting the reaction times thereby avoiding the use of a bifunctional linker. The beads are then divided into N pools. Pool 1 is derivatized with a fluorophore, such as pyrene butyric acid. Pool 2 is derivatized with a 1:3 mixture of a fluorophore, such as pyrene butyric acid, and a non-fluorophore (hereinafter a "doping agent"), such as butyric acid or a different fluorophore, such as perylene butyric acid. Pool N is derivatized with a 1: 3(N-1) ratio of a fluorophore, such as pyrene butyric acid, and a doping agent, such as butyric acid or a different fluorophore, such as perylene butyric acid.
Each of these pools of beads can be differentiated from any other pool of beads by flow cytometry. Each pool of beads may also be differentiated from one another by inspection with the unaided eye, however fewer variables could be encoded this way. Further, different fluorophores with different absorption and emittance wavelengths and multiple fluorophores could be encoded by fluorescence quenching to encode additional variables. The use of multiple fluorophores, the ratio of which is the identifier, has several advantages including the ability to greatly increases the number of variables that can be identified by using the same number of tags and enabling analysis independent of bead size. Also, the same strategy can be applied to prepare beads that can be used to discriminate between library members with redundant molecular weights by fluorescence, preferably by starting with beads with at least 50 pmoles of linker.
In a particularly preferred aspect of the invention a single combinatorial library is prepared, each choice therein being encoded by a tag, preferably using fluorescent label identifiers, and tested for biological activity, preferably without mixing the final pools.
In an especially preferred aspect of the invention the "Combine and Split protocol", as described in Scheme 4 below, is utilized to synthesize encoded beads, preferably with fluorescent label identifiers attached thereto. The "Combine and Split protocol" is advantageous in that it eliminates the need to resynthesize, or parallel synthesize, libraries containing only one or two fluorescent tags. This aspect of the invention is especially attractive from a practical point of view since the encoded beads can be prepared in bulk, prior to the actual synthesis of combinatorial libraries.
An additionally preferred aspect of this invention relates to combinatorial libraries prepared using beads encoded by fluorescent label identifiers and to pharmaceutically active compounds identified by such combinatorial library.
An additionally preferred aspect of this invention relates to combinatorial libraries in which each choice therein is encoded by fluorescent label identifiers and to pharmaceutically active compounds identified by such combinatorial library.
An additionally preferred aspect of this invention relates to combinatorial libraries prepared using beads encoded by fluorescent label identifiers, wherein said beads were obtained by the Combine and Split protocol, and to pharmaceutically active compounds identified by such combinatorial library.
An additionally preferred aspec
Figure imgf000023_0001
his invention relates to combinatorial libraries in which each choice therein is encoded by fluorescent label identifiers, wherein said beads were obtained by the Combine and Split protocol, and to pharmaceutically active compounds identified by such combinatorial library.
An example of a combinatorial library prepared according to the present invention is outlined in Scheme 4 below.
Scheme 4
Pool of Untagged Beads ooooooo
STEP 1
Add permutations (1, 2 and 3 as used in Scheme 4) of identifier T(a) (either by adding varying ratios of a fluorophore and a non-fluorophore or by adding two different fluorescent tags in varying ratios)
Figure imgf000024_0001
Add permutations (1, 2 and 3 as used in Scheme 4) of identifier T(b) (either by adding varying ratios of a fluorophore and a non-fluorophore or by adding two different fluorescent tags in varying ratios)
Figure imgf000024_0002
Combine and Split
Figure imgf000025_0002
STEP 3
Add permutations (1, 2 and 3 as used in Scheme 4) of identifier T(c) (either by adding varying ratios of a fluorophore and a non-fluorophore or by adding two different fluorescent tags in varying ratios)
Figure imgf000025_0001
Figure imgf000026_0001
STEP 4
Conduct Specified Reaction Conditions
Figure imgf000026_0002
as such:
Y1 is encoded by Y2 is encoded by Y3 is encoded by T1c T2c T3c
STEP 5
Combine and Sort by Txa. As used throughout Scheme 4, x is 1, 2 or 3 as utilized above
1
L m $ ww
Figure imgf000027_0001
$ ###
The above T1 a Registry The above T2a Registry The above T3a Registry can be described as can be described as can be described as
Figure imgf000027_0002
using the abbreviated using the abbreviated using the abbreviated terminology terminology terminology
Conduct specified reaction conditions
Figure imgf000027_0003
Using the above abbreviated terminology
as such:
Z1 is encoded by Z2 is encoded by Z3 is encoded by T1a T2a T3a
STEP 6
Combine and sort by Txb .
Figure imgf000028_0001
Conduct specified reaction conditions
χ
Figure imgf000028_0002
:
encoded by T1 b P2 is encoded by T2b P3 is encoded by T3b
STEP 7
Combine and Split
Figure imgf000028_0003
Conduct Specified Reaction Conditions
Figure imgf000029_0001
Group 1 Group 2 Group 3
Scheme 4 outlines the preparation of a combinatorial library in which each choice therein is encoded by a unique identifier. As used in Scheme 4 untagged beads are encoded with the first identifier (as described in Scheme 3). The encoded beads are combined into a single mixture and then separated into groups according to the number of permutations of the second identifier. The beads are then encoded with the second identifier. (The above encoding process is repeated until groups of encoded beads of desired size is obtained). According to Scheme 4, the beads encoded with the second identifier are combined into a single mixture and then separated into groups according to the number of permutations of the third identifier. The beads are then encoded with the third identifier.
Encoded beads prepared according to the above methods and said methods represent preferred embodiments of the claimed invention.
The beads thus prepared are maintained in separate homogeneous pools of like identifiers according to the third identifier and subjected to the first stage (or registry as used herein) of specified reaction conditions. The choices of the first registry are thereinby encoded by the third identifier. The beads are then combined and sorted, preferably by flow cytometry, into homogeneous pools of like identifiers according to the first identifier. The beads thus obtained are maintained in separate pools and subjected to the second stage of specified reaction conditions. The choices of the second registry are thereinby encoded by the first identifier. The beads are then combined and sorted, preferably by flow cytometry, into
homogeneous pools of like identifiers according to the second identifier. The beads thus obtained are maintained in separate pools and subjected to the third stage of specified reaction conditions. The choices of the third registry are thereinby encoded by the second identifier. The beads are then combined and separated into groups according to the number of choices of the forth stage and subjected to the forth stage of specified reaction conditions. The pools of beads thus obtained are maintained in these separate groups and tested for biological activity. The choices of the forth registry are thereinby separately maintained.
As indicated above, each of these groups are separately tested for biological activity and analyzed, preferably by flow cytometry or by cleavage of compounds from individual groups or from smaller sets of individual groups. The exact reaction history of each active can be identified by reading the unique identifier from the corresponding bead. In the above Scheme, if an active compound is found in group 2 then one could analyze the individual bead by fluorescence detection. If T3c, T2a, T2b were present on the bead, then the reaction history of the active structure is: Y3-Z2-P2-Q2.
By the term "Combine and Split protocol" as used herein is analogously described by the steps of Scheme 4 above. The formation of encoded beads by the Combine and Split protocol is analogously described in steps 1 to 4 of Scheme 4. The formation of combinatorial library in which each choice therein is encoded by the Combine and Split protocol is analogously described in steps 1 to 7 of Scheme 4. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. Example 1
Preparation of fluorophore-labeled beads that can be sorted by flow cytometry by differences in the intensity of fluorescence by the method of doping.
Procedure A:
A bifunctional linker such as e-Boc-FMOC-L- lysine (8.4 g, 6 eq., 18 mmol, Novabiochem), an amide coupling agent such as diisopropyl carbodiimide ( 2.3 g, 2.8 ml, 6 eq., 18 mmol, Aldrich) is added to Polyethylene glycol-linked to cross-linked polystyrene beads (Tentagel M NH2, 10 micron particle size, 15.0 g, 3 mmol, Rapp Polymere) suspended in a suitable solvent such as N-methyl pyrrolidine (300 ml) and is agitated overnight The reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 100 ml). The beads are then agitated with 25% piperidine/ DMF (300 ml) for 15 min. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 100 ml), then CH2CI2 (5 x 100 ml), then air dried. Procedure B:
The lysine derivatized beads (5.0 g), as described in Procedure A, are suspended in N-methyl pyrrolidine (100 ml), then a fluorophore such as 1-pyrene butyric acid (1.7 g, 6 eq., 6 mmol, Aldrich) and diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) are added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
The beads are then agitated in 25% TFA/CH2CI2 (100 ml) for 2 h removing the Boc protective group. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried.
The beads are then reacted with a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight. The reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 30 ml), then CH2CI2 (5 x 100 ml), then air dried.
The beads are then re suspended in THF ( 100 ml), and a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried.
Procedure C:
The beads ( 5 g), as prepared in Procedure B, are then suspended in N- methyl pyrrolidine (100 ml) and is then reacted with a monomer such as FMOC-L- glyine (1.8 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Procedure D: The lysine derivatized beads (5.0 g), as described in Procedure A, are suspended in N-methyl pyrrolidine (100 ml), then a fluorophore such as 1-pyrene butyric acid (0.43 g, 1.5 eq., 1.5 mmol), and a doping agent such as butyric acid (0.4 g, 0.41 ml, 4.5 eq., 4.5 mmol) in 1:3 stoichiometry, and diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) are added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
The beads are then agitated in 25% TFA/ CH2CI2 (100 ml) for 2 h removing the Boc protective group. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried.
The beads are then reacted with a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight. The reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 30 ml), then CH2CI2 (5 x 100 ml), then air dried.
The beads are then resuspended in THF (100 ml), and a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried.
Procedure E:
The beads ( 5 g), as prepared in Procedure D, are then suspended in N- methyl pyrrolidine (100 ml) and is then reacted with a monomer such as FMOC-L- alanine (1.9 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Procedure F:
The lysine derivatized beads (5.0 g), as described in Procedure A, are suspended in N-methyl pyrrolidine (100 ml), then a fluorophore such as 1-pyrene butyric acid (0.173 g, 0.6 eq., 0.6 mmol), and a doping agent such as butyric acid (0.48 g, 0.49 ml, 5.4 eq., 5.4 mmol) in 1:9 stoichiometry, and diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) are added, and the reaction is agitated for 3 hours. Th e reaction is filtered through a glass frit under aspirator pressure, washed with DMH ( 5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
The beads are then agitated in 25% TFA/ CH2CI2 (100 ml) for 2 h removing the Boc protective group. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried.
The beads are then reacted with a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight. The reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 30 ml), then CH2CI2 (5 x 100 ml), then air dried.
The beads are then resuspended in THF (100 ml), and a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. Procedure G:
The beads ( 5 g), as prepared in Procedure F, are then suspended in N- methyl pyrrolidine (100 ml) and is then reacted with a monomer such as FMOC-L- phenylalanine (2.3 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Procedure H:
The beads obtained from procedures C, E, and G are then combined and split into 3 equal portions.
Pool H1 is reacted with a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test. Pool H2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Pool H3 is reacted with a monomer such as FMOC-L-phenylalanine (2.3 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Procedure I:
The beads obtained from Procedure H are then combined and split into 3 equal portions.
Pool I1 is reacted with a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Pool I2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Pool I3 is reacted with a monomer such as FMOC-L-phenylalanine (2.3 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Procedure J: The beads obtained from Procedure I are then combined and sorted by flow cytometry into different sublibraries differentiated by the differences in intensity of fluorescence. Sublibrary components have the same first amino acid of the tripeptide.
Sublibrary J1 consists of Gly-X-X or Gly-Gly-Gly, Gly-Gly-Ala, Gly-Gly-Phe, Gly- Ala- Gly, Gly-Ala-Ala, Gly-Ala-Phe, Gly-Phe-Gly, Gly-Phe-Ala, Gly-Phe-Phe. Sublibrary J2 consists of Ala-X-X or Ala-Gly-Gly, Ala-Gly-Ala, Ala-Gly-Phe, Ala- Ala- Gly, Ala-Ala- Ala, Ala-Ala-Phe, Ala-Phe-Gly, Ala-Phe-Ala, Ala-Phe-Phe Sublibrary J3 consists of Phe-X-X or Phe-Gly-Gly, Phe-Gly-Ala, Phe-Gly-Phe, Phe- Ala- Gly, Phe-Ala-Ala, Phe-Ala-Phe, Phe-Phe-Gly, Phe-Phe-Ala, Phe-Phe-Phe
Procedure K:
The beads obtained from Procedure B, D, and F are then combined and split into 3 equal portions.
Pool K1 is reacted with a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Pool K2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Pool K3 is reacted with a monomer such as FMOC-L-phenylalanine (2.3 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test. Procedure L: The beads obtained from Procedure K are then combined and sorted by flow cytometry into different pools differentiated by the differences in intensity of fluorescence.
Pool L1 is reacted with a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Pool L2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Pool L3 is reacted with a monomer such as FMOC-L-phenylalanine (2.3 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Procedure M:
The beads obtained from Procedure L are then combined and split into 3 equal portions.
Pool M1 is reacted with a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Pool M2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test. Pool M3 is reacted with a monomer such as FMOC-L-phenylalanine (2.3 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Procedure N:
The beads obtained from Procedure M are then combined and sorted by flow cytometry into different sublibraries differentiated by the differences in intensity of fluorescence. Sublibrary components have the same second amino acid of the tripeptide.
Sublibrary N1 consists of X-Gly-X or Gly-Gly-Gly, Gly-Gly- Ala, Gly-Gly-Phe, Ala- Gly-Gly, Ala-Gly-Ala, Ala-Gly-Phe, Phe-Gly-Gly, Phe-Gly-Ala, Phe-Gly- Phe
Sublibrary N2 consists of X-Ala-X or Gly-Ala-Gly, Gly- Ala- Ala, Gly-Ala-Phe, Ala- Ala- Gly, Ala- Ala- Ala, Ala-Ala-Phe, Phe-Ala-Gly, Phe-Ala-Ala, Phe-Ala- Phe
Sublibrary N3 consists of X-Phe-X or Gly-Phe-Gly, Gly-Phe-Ala, Gly-Phe-Phe, Ala-Phe- Gly, Ala-Phe-Ala, Ala-Ala-Phe, Phe-Phe-Gly, Phe-Phe-Ala, Phe- Phe-Phe
Procedure O:
The beads (5.0 g), as described in Procedure K, are combined and split into 3 equal portions.
Pool O1 is reacted with a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Pool O2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Pool O3 is reacted with a monomer such as FMOC-L-phenylalanine (2.3 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test. Procedure P:
The beads obtained from Procedure O are then combined and split into 3 equal portions.
Pool P1 is reacted with a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and me reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Pool P2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Pool P3 is reacted with a monomer such as FMOC-L-phenylalanine (2.3 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Procedure Q:
The beads obtained from Procedure P are then combined and sorted by flow cytometry into different pools differentiated by the differences in intensity of fluorescence.
Pool Q1 is reacted with a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2Cl2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Pool Q2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
Pool Q3 is reacted with a monomer such as FMOC-L-phenylalanine (2.3 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
The pools of beads obtained from Procedure Q are already sorted into sublibraries in which the third amino acid of each component is the same the same amino acid of the tripeptide.
Sublibrary Q1 consists of X-X-Gly or Gly-Gly-Gly, Gly-Ala-Gly, Gly-Phe-Gly,
Ala- Gly-Gly, Ala-Ala-Gly, Ala-Phe-Gly, Phe-Gly-Gly, Phe-Ala-Gly, Phe-Phe-
Gly
Sublibrary Q2 consists of X-X-Ala or Gly-Gly- Ala, Gly- Ala- Ala, Gly-Phe- Ala,
Ala-Gly- Ala, Ala- Ala- Ala, Ala-Phe-Ala, Phe-Gly-Ala, Phe-Ala-Ala, Phe-
Phe-Ala
Sublibrary Q3 consists of X-X-Phe or Gly-Gly-Phe, Gly-Ala-Phe, Gly-Phe-Phe,
Ala- Gly-Phe, Ala-Ala-Phe, Ala-Phe-Phe, Phe-Gly-Phe, Phe-Ala-Phe, Phe-Phe- Phe Procedure R:
Individual sublibraries J1, J2, J3, N1, N2, N3, Q1, Q2, and Q3 are tested for biological activity either by cleaving the compounds from the beads with hydroxide or a strong acid such as HF or the compounds are tested on the beads by biopanning or flow cytometry. The results from this testing gives a population analysis of preferred monomers in particular registries or positions.
Example 2
Preparation of fluorophore-labeled beads that can be sorted by flow cytometry by differences in the intensity of fluorescence by the method of labeling with fluorophores whose emission maximum is at different wavelengths.
Procedure:
The methods of Example 1 are used except that the doping reagent is replaced by a second fluorophore such as perylene butyric acid.
While the preferred embodiments of the invention are illustrated by the above, it is to be understood that the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming within the scope of the following claims is reserved.

Claims

What is claimed is:
1. A method of encoding a series of combinatorial libraries which comprises:
a) preparing a first combinatorial library by conducting a specified set of reaction sequences on tagged beads thereinby encoding each choice of the first registry;
b) preparing a second combinatorial library from substantially the same specified set of reaction sequences as the first library wherein the tagged beads are combined and separated prior to the first reaction sequence and the beads are sorted prior to the second reaction sequence, thereinby encoding each choice of the second registry and
c) preparing subsequent libraries according the procedure in b) except that the sort step is performed prior to a different registry in each subsequent library; provided that the number of libraries in the combinatorial library series is equal to the number of registries.
2. A series of combinatorial libraries,
wherein,
a) each individual library is prepared from substantially the same specified set of reaction sequences,
b) the number of libraries is equal to the number of registries in a single library and
c) a different registry is encoded in each library.
3. The series of combinatorial libraries of claim 2 in which the encoded registries are fluorescently tagged.
4. The series of combinatorial libraries of claim 3 in which the encoded registries are encoded with fluorescent label identifiers.
5. An individual combinatorial library of claim 4.
6. A method for identifying compounds having desired characteristics which comprises:
a) preparing a series of combinatorial libraries as described in claim 1; b) testing each library in an assay which identifies compounds having desired characteristics and
c) subjecting each library to flow cytometry, thereby obtaining groups of beads which have undergone a known reaction history.
7. Beads encoded with a fluorescent label identifier.
8. The beads of claim 7 prepared by the Combine and Split protocol.
9. A combinatorial library in which each choice therein is encoded by fluorescent label identifiers.
10. A combinatorial library of claim 9 prepared by the Combine and Split protocol.
11. A pharmaceutically active compound identified by a combinatorial library of claim 10.
12. A method of preparing combinatorial libraries which comprises sorting tagged solid support beads by flow cytometry prior to subjection to a specified set of reaction sequences.
13. A combinatorial library prepared by the method of claim 12.
PCT/US1995/006392 1994-05-23 1995-05-23 Encoded combinatorial libraries WO1995032425A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP7530459A JPH10500951A (en) 1994-05-23 1995-05-23 Coded combinatorial library
US08/537,752 US6210900B1 (en) 1995-05-23 1995-05-23 Method of encoding a series of combinatorial libraries and developing structure activity relationships
EP95920576A EP0763202A4 (en) 1994-05-23 1995-05-23 Encoded combinatorial libraries

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US24779394A 1994-05-23 1994-05-23
US08/247,793 1994-05-23
US26733394A 1994-06-28 1994-06-28
US08/267,333 1994-06-28
US38254295A 1995-02-01 1995-02-01
US08/382,542 1995-02-01
US41043695A 1995-03-23 1995-03-23
US08/410,436 1995-03-23

Publications (1)

Publication Number Publication Date
WO1995032425A1 true WO1995032425A1 (en) 1995-11-30

Family

ID=27500266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/006392 WO1995032425A1 (en) 1994-05-23 1995-05-23 Encoded combinatorial libraries

Country Status (3)

Country Link
EP (1) EP0763202A4 (en)
JP (1) JPH10500951A (en)
WO (1) WO1995032425A1 (en)

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
WO1999006839A1 (en) * 1997-08-01 1999-02-11 Novalon Pharmaceutical Corporation Method of identifying and developing drug leads
WO1999049315A1 (en) * 1998-03-24 1999-09-30 Rigel Pharmaceuticals, Inc. Small molecule library screening using facs
WO1999064867A1 (en) * 1997-12-04 1999-12-16 Amersham Pharmacia Biotech Uk Limited Multiple assay method
US6054047A (en) * 1998-03-27 2000-04-25 Synsorb Biotech, Inc. Apparatus for screening compound libraries
WO2000032542A1 (en) * 1998-11-30 2000-06-08 The University Of Queensland Carriers for combinatorial compound libraries
WO2000061281A1 (en) * 1999-04-09 2000-10-19 Glaxo Group Limited Encoding scheme for solid phase chemical libraries
WO2001080622A2 (en) * 2000-04-26 2001-11-01 Streamline Proteomics Apparatus and methods for assays of one or more analytes
WO2002064829A2 (en) * 2001-02-13 2002-08-22 Smartbead Technologies Limited Biochemical method and apparatus for detecting genetic characteristics
WO2002065123A2 (en) * 2001-02-13 2002-08-22 Smartbead Technologies Limited Biochemical method and apparatus for detecting protein characteristics
US6489116B2 (en) 2000-01-24 2002-12-03 Phylos, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US6492125B2 (en) * 1998-09-03 2002-12-10 Trellis Bioscience, Inc. Method to assess library X library interactions
US6506342B1 (en) * 1997-06-19 2003-01-14 Robert D. Frankel Tracking apparatus and method for use with combinatorial synthesis processes
US6602685B1 (en) 1998-08-17 2003-08-05 Phylos, Inc. Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules
US6607921B1 (en) 1998-03-27 2003-08-19 Ole Hindsgaul Methods for screening compound libraries
US6613575B1 (en) 1998-03-27 2003-09-02 Ole Hindsgaul Methods for screening compound libraries
US6627453B1 (en) 1998-03-27 2003-09-30 Ole Hindsgaul Methods for screening compound libraries
WO2005061094A1 (en) 2003-12-22 2005-07-07 Versamatrix A/S Identification of encoded beads
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
WO2010109168A2 (en) 2009-03-23 2010-09-30 Academisch Ziekenhuis Leiden Also Acting Under The Name "Leiden University Medical Center" (Lumc) Angiogenesis methods, medicaments and agents
US7869011B2 (en) 2003-12-22 2011-01-11 Novo Norkisk A/S Apparatus and methods for analysis and sorting of particles such as polymer beads
WO2011098484A1 (en) 2010-02-09 2011-08-18 Academisch Ziekenhuis Leiden Also Acting Under The Name "Leiden University Medical Center" (Lumc) Trichodysplasia spinulosa- associated polyomavirus (tsv)
WO2012093258A2 (en) 2011-01-05 2012-07-12 Imperial Innovations Limited Treatment and screening
US8222047B2 (en) 2008-09-23 2012-07-17 Quanterix Corporation Ultra-sensitive detection of molecules on single molecule arrays
US8236574B2 (en) 2010-03-01 2012-08-07 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
EP2573563A1 (en) 2007-12-20 2013-03-27 Heptares Therapeutics Limited Screening
US8415171B2 (en) 2010-03-01 2013-04-09 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
US8460879B2 (en) 2006-02-21 2013-06-11 The Trustees Of Tufts College Methods and arrays for target analyte detection and determination of target analyte concentration in solution
US8703915B2 (en) 2009-06-22 2014-04-22 Heptares Therapeutics Limited Mutant proteins and methods for producing them
US8748182B2 (en) 2007-12-08 2014-06-10 Heptares Therapeutics Limited Mutant proteins and methods for producing them
US8785135B2 (en) 2007-03-22 2014-07-22 Heptares Therapeutics Limited Mutant G-protein coupled receptors and methods for selecting them
US9081020B2 (en) 2008-02-11 2015-07-14 Heptares Therapeutics Limited Mutant proteins and methods for selecting them
US9110025B2 (en) 2010-03-01 2015-08-18 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
WO2016116760A2 (en) 2015-01-21 2016-07-28 Cancer Research Technology Limited Inhibitors
US9678068B2 (en) 2010-03-01 2017-06-13 Quanterix Corporation Ultra-sensitive detection of molecules using dual detection methods
WO2017129998A1 (en) 2016-01-29 2017-08-03 Heptares Therapeutics Limited G proteins
US9809838B2 (en) 2007-08-30 2017-11-07 Trustees Of Tufts College Methods for determining the concentration of an analyte in solution
US9932626B2 (en) 2013-01-15 2018-04-03 Quanterix Corporation Detection of DNA or RNA using single molecule arrays and other techniques
US9952237B2 (en) 2011-01-28 2018-04-24 Quanterix Corporation Systems, devices, and methods for ultra-sensitive detection of molecules or particles
US10393759B2 (en) 2011-04-12 2019-08-27 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
WO2020049130A1 (en) 2018-09-05 2020-03-12 Valerie Nicholas Carl Kristoffer Methods
US11237171B2 (en) 2006-02-21 2022-02-01 Trustees Of Tufts College Methods and arrays for target analyte detection and determination of target analyte concentration in solution

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542463A (en) * 1999-04-15 2002-12-10 バーチャル・アレイズ・インコーポレーテッド Combinatorial chemical library with indices at code locations
AU2001232231A1 (en) * 2000-02-07 2001-08-20 Kyowa Medex Co., Ltd Method for detecting substance

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NATURE, Volume 354, issued 07 November 1991, LAM et al., "A New Type of Synthetic Peptide Library for Identifying Ligand-Binding Activity", pages 82-84. *
PROC. NATL. ACAD. SCI. U.S.A., Volume 90, issued December 1993, OHLMEYER et al., "Complex Synthetic Chemical Libraries Indexed with Molecular Tags", pages 10922-10926. *
PROC. NATL. ACAD. SCI. U.S.A., Volume 90, issued November 1993, NEEDELS et al., "Generation and Screening of an Oligonucleotide-Encoded Synthetic Peptide Library", pages 10700-10704. *
See also references of EP0763202A4 *

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
US6506342B1 (en) * 1997-06-19 2003-01-14 Robert D. Frankel Tracking apparatus and method for use with combinatorial synthesis processes
WO1999006839A1 (en) * 1997-08-01 1999-02-11 Novalon Pharmaceutical Corporation Method of identifying and developing drug leads
WO1999064867A1 (en) * 1997-12-04 1999-12-16 Amersham Pharmacia Biotech Uk Limited Multiple assay method
WO1999049315A1 (en) * 1998-03-24 1999-09-30 Rigel Pharmaceuticals, Inc. Small molecule library screening using facs
US6455263B2 (en) 1998-03-24 2002-09-24 Rigel Pharmaceuticals, Inc. Small molecule library screening using FACS
US6355163B2 (en) 1998-03-27 2002-03-12 Ole Hindsgaul Apparatus for screening compound libraries
US6607921B1 (en) 1998-03-27 2003-08-19 Ole Hindsgaul Methods for screening compound libraries
US6387257B1 (en) 1998-03-27 2002-05-14 Ole Hindsgaul Apparatus for screening compound libraries
US6395169B1 (en) 1998-03-27 2002-05-28 Ole Hindgual Apparatus for screening compound libraries
US6723235B2 (en) 1998-03-27 2004-04-20 Ole Hindsgaul Apparatus for screening compound libraries
US6720190B1 (en) 1998-03-27 2004-04-13 Ole Hindsgaul Methods for screening compound libraries
US6054047A (en) * 1998-03-27 2000-04-25 Synsorb Biotech, Inc. Apparatus for screening compound libraries
US6656739B2 (en) 1998-03-27 2003-12-02 Ole Hindsgaul Methods for screening compound libraries
US6613575B1 (en) 1998-03-27 2003-09-02 Ole Hindsgaul Methods for screening compound libraries
US6649415B1 (en) 1998-03-27 2003-11-18 Ole Hindsgaul Methods for screening compound libraries
US6627453B1 (en) 1998-03-27 2003-09-30 Ole Hindsgaul Methods for screening compound libraries
US6602685B1 (en) 1998-08-17 2003-08-05 Phylos, Inc. Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules
US6492125B2 (en) * 1998-09-03 2002-12-10 Trellis Bioscience, Inc. Method to assess library X library interactions
WO2000032542A1 (en) * 1998-11-30 2000-06-08 The University Of Queensland Carriers for combinatorial compound libraries
WO2000061281A1 (en) * 1999-04-09 2000-10-19 Glaxo Group Limited Encoding scheme for solid phase chemical libraries
US6489116B2 (en) 2000-01-24 2002-12-03 Phylos, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
WO2001080622A3 (en) * 2000-04-26 2012-02-02 Streamline Proteomics Apparatus and methods for assays of one or more analytes
WO2001080622A2 (en) * 2000-04-26 2001-11-01 Streamline Proteomics Apparatus and methods for assays of one or more analytes
WO2002064829A3 (en) * 2001-02-13 2002-12-12 Smartbead Technologies Ltd Biochemical method and apparatus for detecting genetic characteristics
WO2002065123A3 (en) * 2001-02-13 2002-12-12 Smartbead Technologies Ltd Biochemical method and apparatus for detecting protein characteristics
WO2002065123A2 (en) * 2001-02-13 2002-08-22 Smartbead Technologies Limited Biochemical method and apparatus for detecting protein characteristics
WO2002064829A2 (en) * 2001-02-13 2002-08-22 Smartbead Technologies Limited Biochemical method and apparatus for detecting genetic characteristics
WO2005061094A1 (en) 2003-12-22 2005-07-07 Versamatrix A/S Identification of encoded beads
US7869011B2 (en) 2003-12-22 2011-01-11 Novo Norkisk A/S Apparatus and methods for analysis and sorting of particles such as polymer beads
US8460878B2 (en) 2006-02-21 2013-06-11 The Trustees Of Tufts College Methods and arrays for detecting cells and cellular components in small defined volumes
US10261089B2 (en) 2006-02-21 2019-04-16 Trustees Of Tufts College Methods and arrays for target analyte detection and determination of target analyte concentration in solution
US11874279B2 (en) 2006-02-21 2024-01-16 Trustees Of Tufts College Methods and arrays for target analyte detection and determination of target analyte concentration in solution
US9395359B2 (en) 2006-02-21 2016-07-19 Trustees Of Tufts College Methods and arrays for target analyte detection and determination of target analyte concentration in solution
US8492098B2 (en) 2006-02-21 2013-07-23 The Trustees Of Tufts College Methods and arrays for target analyte detection and determination of reaction components that affect a reaction
US8460879B2 (en) 2006-02-21 2013-06-11 The Trustees Of Tufts College Methods and arrays for target analyte detection and determination of target analyte concentration in solution
US11237171B2 (en) 2006-02-21 2022-02-01 Trustees Of Tufts College Methods and arrays for target analyte detection and determination of target analyte concentration in solution
US11673938B2 (en) 2007-03-22 2023-06-13 Heptares Therapeutics Limited Mutant G-protein coupled receptors and methods for selecting them
US8785135B2 (en) 2007-03-22 2014-07-22 Heptares Therapeutics Limited Mutant G-protein coupled receptors and methods for selecting them
US9809838B2 (en) 2007-08-30 2017-11-07 Trustees Of Tufts College Methods for determining the concentration of an analyte in solution
US8748182B2 (en) 2007-12-08 2014-06-10 Heptares Therapeutics Limited Mutant proteins and methods for producing them
EP2573563A1 (en) 2007-12-20 2013-03-27 Heptares Therapeutics Limited Screening
US8790933B2 (en) 2007-12-20 2014-07-29 Heptares Therapeutics Limited Screening
US9260505B2 (en) 2007-12-20 2016-02-16 Heptares Therapeutics Limited Methods for screening for binding partners of G-protein coupled receptors
US10126313B2 (en) 2007-12-20 2018-11-13 Heptares Therapeutics Limited Methods for screening for binding partners of G-protein coupled receptors
US9081020B2 (en) 2008-02-11 2015-07-14 Heptares Therapeutics Limited Mutant proteins and methods for selecting them
US8222047B2 (en) 2008-09-23 2012-07-17 Quanterix Corporation Ultra-sensitive detection of molecules on single molecule arrays
US8846415B2 (en) 2008-09-23 2014-09-30 Quanterix Corporation Ultra-sensitive detection of molecules on single molecule arrays
WO2010109168A2 (en) 2009-03-23 2010-09-30 Academisch Ziekenhuis Leiden Also Acting Under The Name "Leiden University Medical Center" (Lumc) Angiogenesis methods, medicaments and agents
US8703915B2 (en) 2009-06-22 2014-04-22 Heptares Therapeutics Limited Mutant proteins and methods for producing them
WO2011098484A1 (en) 2010-02-09 2011-08-18 Academisch Ziekenhuis Leiden Also Acting Under The Name "Leiden University Medical Center" (Lumc) Trichodysplasia spinulosa- associated polyomavirus (tsv)
US9678068B2 (en) 2010-03-01 2017-06-13 Quanterix Corporation Ultra-sensitive detection of molecules using dual detection methods
US10725032B2 (en) 2010-03-01 2020-07-28 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
US9482662B2 (en) 2010-03-01 2016-11-01 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
US8236574B2 (en) 2010-03-01 2012-08-07 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
US9846155B2 (en) 2010-03-01 2017-12-19 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
US11619631B2 (en) 2010-03-01 2023-04-04 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
US9551663B2 (en) 2010-03-01 2017-01-24 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
US9310360B2 (en) 2010-03-01 2016-04-12 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
US9110025B2 (en) 2010-03-01 2015-08-18 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
US8415171B2 (en) 2010-03-01 2013-04-09 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
US10989713B2 (en) 2010-03-01 2021-04-27 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
WO2012093258A2 (en) 2011-01-05 2012-07-12 Imperial Innovations Limited Treatment and screening
US9952237B2 (en) 2011-01-28 2018-04-24 Quanterix Corporation Systems, devices, and methods for ultra-sensitive detection of molecules or particles
US11112415B2 (en) 2011-01-28 2021-09-07 Quanterix Corporation Systems, devices, and methods for ultra-sensitive detection of molecules or particles
US10393759B2 (en) 2011-04-12 2019-08-27 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
US11275092B2 (en) 2011-04-12 2022-03-15 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
US10640814B2 (en) 2013-01-15 2020-05-05 Quanterix Corporation Detection of DNA or RNA using single molecule arrays and other techniques
US9932626B2 (en) 2013-01-15 2018-04-03 Quanterix Corporation Detection of DNA or RNA using single molecule arrays and other techniques
US10808031B2 (en) 2015-01-21 2020-10-20 Cancer Research Technology Limited Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis
WO2016116760A2 (en) 2015-01-21 2016-07-28 Cancer Research Technology Limited Inhibitors
US11919959B2 (en) 2015-01-21 2024-03-05 Cancer Research Technology Limited Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis
US10738287B2 (en) 2016-01-29 2020-08-11 Heptares Therapeutics Limited G proteins
US11339383B2 (en) 2016-01-29 2022-05-24 Heptares Therapeutics Limited G proteins
WO2017129998A1 (en) 2016-01-29 2017-08-03 Heptares Therapeutics Limited G proteins
WO2020049130A1 (en) 2018-09-05 2020-03-12 Valerie Nicholas Carl Kristoffer Methods

Also Published As

Publication number Publication date
EP0763202A4 (en) 1998-12-09
JPH10500951A (en) 1998-01-27
EP0763202A1 (en) 1997-03-19

Similar Documents

Publication Publication Date Title
WO1995032425A1 (en) Encoded combinatorial libraries
US6210900B1 (en) Method of encoding a series of combinatorial libraries and developing structure activity relationships
Lebl et al. One‐bead–one‐structure combinatorial libraries
Früchtel et al. Organic chemistry on solid supports
US5541061A (en) Methods for screening factorial chemical libraries
AU686186B2 (en) Topologically segregated, encoded solid phase libraries
AU756945B2 (en) Color-encoding and in-situ interrogation of matrix-coupled chemical compounds
Jacobs et al. Combinatorial chemistry—applications of light-directed chemical synthesis
US5840485A (en) Topologically segregated, encoded solid phase libraries
Barnes et al. Recent developments in the encoding and deconvolution of combinatorial libraries
WO2003038558A2 (en) Device and methods for directed synthesis of chemical libraries
Hlavac et al. Practical aspects of combinatorial solid-phase synthesis
Schmuck et al. The development of artificial receptors for small peptides using combinatorial approaches
US20050095638A1 (en) Factorial chemical libraries
US20050100968A1 (en) Self-encoded combinatorial synthesis of compound multiplets
WO2023100976A1 (en) Peptide-immobilized bead library
WO1997029371A1 (en) Sulfur ratio tagging method for combinatorial libraries
Krämer et al. Encoding technologies
Kushwaha et al. A Novel Methods Used in Drug Discovery
Lebl et al. Felder zyxwvutsrqponmlkj
G Newton Editorial Biologicals & Immunologicals: Patenting combinatorial libraries and associated technologies
Ambre et al. Combinatorial Chemistry: Role in Lead Discovery
CA2392919A1 (en) Systems and methods to facilitate multiple order combinatorial chemical processes
US20030211536A1 (en) Systems and methods to facilitate multiple order combinatorial chemical processes
Li How to Optimize Reactions for Solid-Phase Synthesis of Combinatorial Libraries Using RF-Tagged Microreactors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US US US US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 08537752

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1995920576

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995920576

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995920576

Country of ref document: EP